Avitobra™
Therapy for Bacterial Lung Infections

Avitobra

Aarokiyam: AVITOBRA

Aarokiyam presents AVITOBRA, a pharmaceutical-grade tobramycin inhalation solution that can possibly be provided directly to the lungs using a nebuliser. For patients with cystic fibrosis who have persistent Pseudomonas aeruginosa colonisation, this Tobramycin Inhalation Solution, IP 300mg/5ml in sterile ampoules, provides a tried-and-true method of treating chronic lung infections.

What is AVITOBRA (Tobramycin Nebulizer Solution) ?

AVITOBRA is Tobramycin nebuliser solution—a powerful aminoglycoside antibiotic prepared in a single-dose, nebuliser-ready ampoule. Each 5 mL dose contains 300 mg tobramycin (IP standard) with isotonic saline, pH-balanced at 6.0 using sulfuric acid and sodium hydroxide.

How to Use Tobramycin Inhalation Solution, IP 300mg/5ml

  • Wash hands thoroughly before handling ampoule.
  • Twist open single-dose ampoule containing Tobramycin Inhalation Solution.
  • Pour entire content into nebuliser cup.
  • Assemble nebuliser and mouthpiece/mask as per instructions.
  • Inhale the mist slowly and deeply until the cup is empty (~15 minutes).
  • Clean nebuliser components after each use.

Safety & Precautions about Tobramycin Inhalation Solution, IP 300mg/5ml (AVITOBRA)

Do not use Tobramycin nebuliser solution if:

You are allergic to aminoglycosides, like amikacin and gentamicin.

You are nursing or pregnant without first seeing a doctor.

Use with caution if:

  • You have kidney disease (monitor renal function).
  • You have hearing problems or tinnitus (risk of ototoxicity).
  • You have neuromuscular disorders such as myasthenia gravis.

Possible Side Effects:

  • Voice changes or hoarseness
  • Cough or throat irritation
  • Mild chest tightness

Rare: hearing loss, dizziness, kidney function changes

Tip: Report persistent ringing in the ears or balance problems immediately.

Advantages of AVITOBRA

  • High lung concentration, low systemic exposure
  • Convenient IP 300 mg/5 ml dosing
  • Reduced hospital visits due to at-home nebulisation
  • Proven efficacy against Pseudomonas aeruginosa in cystic fibrosis patients

Patient Guidance

  • Always complete full 28-day cycle unless directed otherwise.
  • Follow on/off cycle schedule strictly to prevent bacterial resistance.
  • Use bronchodilator before AVITOBRA if you have severe bronchospasm.
  • Do not share nebuliser equipment.
  • Keep out of reach of children.

Indications

This Tobramycin nebuliser solution is indicated for adults and children aged 6 years and older with cystic fibrosis who are chronically infected with Pseudomonas aeruginosa. It helps reduce bacterial load, improve lung function, and manage exacerbations.

Mechanism of Action

AVITOBRA works locally within the lungs, disrupting bacterial protein synthesis to stop P. aeruginosa growth. This targeted action minimizes systemic side effects while optimizing respiratory delivery.

Dosage & Administration of Tobramycin Inhalation Solution, IP 300mg/5ml

Parameter

Recommendation


Dosage

300 mg (5 mL) twice daily

Treatment cycle

28 days on → 28 days off

Nebulization

~15 minutes via approved compressor system

Dosage interval

~12 hours apart; minimum 6-hour gap 

Contraindications & Precautions

Contraindicated in patients with known hypersensitivity to aminoglycosides.

Bronchospasm: May occur during inhalation; administer first dose under supervision and pre-treat with bronchodilator if needed.

Ototoxicity: Monitor for tinnitus or hearing loss; a sentinel symptom requiring audiometric evaluation.

Nephrotoxicity: Though rare with inhaled tobramycin, renal function should be monitored, particularly in at-risk patients.

Neuromuscular impairment: Use with caution in patients with neuromuscular disorders such as myasthenia gravis.

Monitoring & Resistance

Regular serum concentrations monitoring is recommended for those with renal or auditory dysfunction—the target is < 2 µg/mL. Long-term cycles may increase P. aeruginosa MIC values, possibly reducing response over time.

Summary – Why Choose AVITOBRA (Tobramycin Inhalation Solution, IP 300mg/5ml) ?

Arokium’s AVITOBRA is a scientifically formulated Tobramycin Inhalation Solution, IP 300mg/5ml.  In fact, this solution is the solution to deal with chronic lung infections. It is a boon especially for cystic fibrosis patients. By delivering high concentrations of the antibiotic directly to the lungs through a tobramycin nebulizer solution, AVITOBRA effectively suppresses persistent Pseudomonas aeruginosa infections. Usually this solution is often resistant to conventional therapies.

According to doctors, systemic antibiotics are unevenly distributed and carry a high risk of kidney and ear toxicity. This targeted inhalation therapy maximizes local antibacterial activity and can significantly reduce systemic exposure. The result is a clinically proven method that not only improves lung function. Not only that, but it is also remarkably effective in reducing the frequency of exacerbations. This solution also helps maintain long-term respiratory stability and improves patients’ overall quality of life.

With its precise IP 300 mg/5 ml formulation, convenient single-dose ampoule, and compatibility with standard nebulizer systems, AVITOBRA is a safe, reliable solution for patients with chronic lung infections. Not only that, AVITOBRA also enables effective long-term management options.

Contact Us

Want to discuss bulk orders?

Please complete the online form if you have any questions or would like to talk about large orders. When you require any information, our employees will get back to you right away. To satisfy your healthcare demands, we at Aarokiyam Lifescience are dedicated to offering top-notch products and outstanding service.

Discover the Aarokiyam difference, where compassionate care and cutting-edge inhalation therapies combine to bring better health to life.